The FDA approved updated COVID-19 booster shots from Pfizer, Moderna, and Novavax targeting a currently circulating coronavirus strain but limited authorization to high-risk groups, including older adults and those with underlying health conditions. Emergency use authorizations for broader populations were rescinded, narrowing access primarily to vulnerable individuals. These regulatory changes come amid rising COVID-19 cases in the U.S. and follow shifts in vaccination policy emphasizing shared clinical decision-making for healthy children and adults. Pfizer’s booster is authorized for ages 5 to 64 with high-risk conditions, Moderna’s for 6 months to 64 years with risk, and Novavax’s for high-risk individuals aged 12 and older. The adjusted authorization reflects evolving public health strategies in the pandemic’s progression.